The Cancer Letter

Inside information on cancer research and drug development

Clinical

Two Opdivo trials show three-year survival in patients with previously treated advanced NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Bristol-Myers Squibb announced three-year overall survival data from CheckMate-017 and CheckMate-057, two pivotal phase III randomized studies evaluating Opdivo versus docetaxel in patients with previously treated metastatic non-small cell lung cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

CAP publishes guideline for PD-L1 testing for lung cancer

The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.
Table of Contents

Login

Looking for IP Login?